Stocks · News reference
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points
AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial
AstraZeneca shares are trading higher after the company and Amgen reported that TEZSPIRE demonstrated meaning improvements in histologic remission and dysphagia in a Phase 3 CROSSING trial for eosinophilic esophagitis.
'A Surprisingly Large Amount Of Your Investment Is Divided Across Just 7 Companies' — Former Investment Banker Says She's Changing How She Invests
The S&P 500 has long been a favorite among investors looking to build wealth, with historical annual returns averaging around 10%. But former investment banker Nischa Shah says she’s changing how she invests, and